Johnson and Johnson 2015 Annual Report Download - page 13

Download and view the complete annual report

Please find page 13 of the 2015 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 112

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112

PART I
Item 1. Business
General
Johnson & Johnson and its subsidiaries (the “Company”) have approximately 127,100 employees worldwide engaged in
the research and development, manufacture and sale of a broad range of products in the health care field. Johnson &
Johnson is a holding company, which has more than 250 operating companies conducting business in virtually all
countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson &
Johnson was incorporated in the State of New Jersey in 1887.
The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic
operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the
Company’s three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters
provided by the Committee, senior management groups at U.S. and international operating companies are each
responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the
business segments is, with limited exceptions, managed by residents of the country where located.
Segments of Business
The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. Additional
information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments
and operating results under: Item 7 “Management’s Discussion and Analysis of Results of Operations and Financial
Condition” of this Report; and Note 18 “Segments of Business and Geographic Areas” of the Notes to Consolidated
Financial Statements included in Item 8 of this Report.
Consumer
The Consumer segment includes a broad range of products used in the baby care, oral care, skin care, over-the-counter
pharmaceutical, women’s health and wound care markets. Baby Care includes the JOHNSON’S®line of products. Oral
Care includes the LISTERINE®product line. Major brands in Skin Care include the AVEENO®; CLEAN & CLEAR®;
DABAO™; JOHNSON’S®Adult; LE PETITE MARSEILLAIS®; LUBRIDERM®; NEUTROGENA®; and RoC®product lines.
Over-the-counter medicines include the broad family of TYLENOL®acetaminophen products; SUDAFED®cold, flu and
allergy products; BENADRYL®and ZYRTEC®allergy products; MOTRIN®IB ibuprofen products; and the PEPCID®line
of heartburn products. Major brands in Women’s Health outside of North America are STAYFREE®and CAREFREE®
sanitary pads and o.b.®tampon brands. Wound Care brands include the BAND-AID®Brand Adhesive Bandages and
NEOSPORIN®First Aid product lines. These products are marketed to the general public and sold both to retail outlets
and distributors throughout the world.
Pharmaceutical
The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory
bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and
tuberculosis), neuroscience (e.g., Alzheimer’s disease, mood disorders and schizophrenia), oncology (e.g., prostate
cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and
diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care
professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE®(infliximab), a
treatment for a number of immune-mediated inflammatory diseases; SIMPONI®(golimumab), a subcutaneous treatment
for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and
moderately active to severely active ulcerative colitis; SIMPONI ARIA®(golimumab), an intravenous treatment for adults
with moderate to severe rheumatoid arthritis; STELARA®(ustekinumab), a treatment for adults with moderate to severe
plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO®/
SOVRIAD®(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA®(darunavir),
EDURANT®(rilpivirine), and PREZCOBIX®/REZOLSTA®(darunavir/cobicistat), antiretroviral medicines for the
Johnson & Johnson 2015 Annual Report •1